Post-marketing analysis for biosimilar CT-P13 in inflammatory bowel disease compared with external data of originator infliximab in Japan.

S, Sagami; K, Nishikawa; F, Yamada; Y, Suzuki; M, Watanabe; T, Hibi

doi:10.1111/jgh.15399

Public

Post-marketing analysis for biosimilar CT-P13 in inflammatory bowel disease compared with external data of originator infliximab in Japan.

Shared by NobleBlocks on Jan 31, 2021 • 12:00 AM UTC

Authors:

Sagami S

Nishikawa K

Yamada F

Abstract

Background and aim CT-P13, an infliximab (IFX) biosimilar, was approved for treatment of inflammatory bowel disease. However, no comparison with the originator IFX in this indication has been conducted in Japan where endemic levels of tuberculosis and hepatitis virus infection are not low. We evalua...

Subject

Post-marketing Surveillance

Ibd

Database Search

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!